Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17143228 | 0.77 | KMT2A (0.53) | POLBMEN1KMT2A | |
| SCHEMBL17148160 | 0.76 | NPSR1 (0.46) | CYP2D6L3MBTL1POLBCYP1A2ALDH1A1 | |
| SCHEMBL20205265 | 0.76 | GAA (0.36) | L3MBTL1TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL17142666 | 0.75 | PLD2 (0.45) | L3MBTL1ALDH1A1 | |
| SCHEMBL17148277 | 0.75 | KMT2A (0.44) | L3MBTL1TDP1POLBMEN1KMT2A | |
| SCHEMBL17142895 | 0.73 | KMT2A (0.46) | HTTL3MBTL1POLBMEN1KMT2A | |
| SCHEMBL18216319 | 0.72 | CHRM4 (0.39) | L3MBTL1POLB | |
| SCHEMBL18216447 | 0.72 | CYP2D6 (0.40) | HTTCYP2D6L3MBTL1TDP1POLB | |
| SCHEMBL17143115 | 0.68 | SMN1; SMN2 (0.54) | L3MBTL1TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL17888294 | 0.68 | NPSR1 (0.72) | HTTCYP2D6POLBCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | HTT 1235/4885CYP2D6 278/4885L3MBTL1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.